Rebecca Miksad, MD, MPH, MMS
Rebecca Miksad, MD, MPH, MMS
Associate Professor, Boston University
Verified email at - Homepage
Cited by
Cited by
Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade
PJ Johnson, S Berhane, C Kagebayashi, S Satomura, M Teng, ...
Journal of Clinical Oncology 33 (6), 550, 2015
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study
AX Zhu, DV Sahani, DG Duda, E di Tomaso, M Ancukiewicz, OA Catalano, ...
Journal of clinical oncology 27 (18), 3027, 2009
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors
JA Chan, K Stuart, CC Earle, JW Clark, P Bhargava, R Miksad, ...
Journal of Clinical Oncology 30 (24), 2963, 2012
cHCC‐CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation
E Brunt, S Aishima, PA Clavien, K Fowler, Z Goodman, G Gores, A Gouw, ...
Hepatology 68 (1), 113-126, 2018
Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer
A Mahadevan, S Jain, M Goldstein, R Miksad, D Pleskow, M Sawhney, ...
International Journal of Radiation Oncology* Biology* Physics 78 (3), 735-742, 2010
Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer
A Mahadevan, R Miksad, M Goldstein, R Sullivan, A Bullock, ...
International Journal of Radiation Oncology* Biology* Physics 81 (4), e615-e622, 2011
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
AX Zhu, TA Abrams, R Miksad, LS Blaszkowsky, JA Meyerhardt, H Zheng, ...
Cancer 117 (22), 5094-5102, 2011
Quality of life implications of bisphosphonate‐associated osteonecrosis of the jaw
RA Miksad, KC Lai, TB Dodson, SB Woo, NS Treister, O Akinyemi, ...
The oncologist 16 (1), 121-132, 2011
Harnessing the power of real‐world evidence (RWE): a checklist to ensure regulatory‐grade data quality
RA Miksad, AP Abernethy
Clinical Pharmacology & Therapeutics 103 (2), 202-205, 2018
Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma
ZR Qian, DA Rubinson, JA Nowak, V Morales-Oyarvide, RF Dunne, ...
JAMA oncology 4 (3), e173420-e173420, 2018
Effect of high-dose vs standard-dose vitamin D3 supplementation on progression-free survival among patients with advanced or metastatic colorectal cancer: the SUNSHINE …
K Ng, HS Nimeiri, NJ McCleary, TA Abrams, MB Yurgelun, JM Cleary, ...
Jama 321 (14), 1370-1379, 2019
Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis
R Miao, H Luo, H Zhou, G Li, D Bu, X Yang, X Zhao, H Zhang, S Liu, ...
Journal of hepatology 61 (4), 840-849, 2014
Clinical cancer advances 2017: annual report on progress against cancer from the American Society of Clinical Oncology
HJ Burstein, L Krilov, JB Aragon-Ching, NN Baxter, EG Chiorean, ...
Journal of Clinical Oncology 35 (12), 1341-1367, 2017
Generating real-world tumor burden endpoints from electronic health record data: comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting …
SD Griffith, M Tucker, B Bowser, G Calkins, C Chang, E Guardino, ...
Advances in therapy 36, 2122-2136, 2019
Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer
S Khozin, RA Miksad, J Adami, M Boyd, NR Brown, A Gossai, I Kaganman, ...
Cancer 125 (22), 4019-4032, 2019
Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma
A Mahadevan, N Dagoglu, J Mancias, K Raven, K Khwaja, JF Tseng, ...
Journal of Cancer 6 (11), 1099, 2015
Hepatocellular carcinoma with portal vein tumor involvement: best management strategies
PH Liu, TI Huo, RA Miksad
Seminars in liver disease 38 (03), 242-251, 2018
Progression-free survival as a surrogate endpoint in advanced breast cancer
RA Miksad, V Zietemann, R Gothe, R Schwarzer, A Conrads-Frank, ...
International journal of technology assessment in health care 24 (4), 371-383, 2008
Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?
J Clin Oncol 25, 4506-4507, 2007
An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non–small-cell lung cancer
M Stewart, AD Norden, N Dreyer, HJ Henk, AP Abernethy, E Chrischilles, ...
JCO clinical cancer informatics 3, 1-15, 2019
The system can't perform the operation now. Try again later.
Articles 1–20